Rezafungin for Injection

DRUG2 trials

Conditions

AspergillusCandidemiaFungal InfectionFungemiaInvasive CandidiasesInvasive CandidiasisInvasive Fungal DiseaseMold Infection

Phase 3

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

CompletedNCT03667690

Cidara Therapeutics Inc.Candidemia, Fungal Infection, Invasive Candidiases +1

Start: 2018-10-07End: 2021-10-07Updated: 2023-01-06

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

CompletedNCT04368559

Mundipharma Research LimitedAspergillus, Candidemia, Fungal Infection +7

Start: 2020-05-11End: 2026-01-29Updated: 2026-04-13

2025-11-011 citations

Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study

Open Forum Infectious Diseases2025-08-291 citations

Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin.

2024-11-221 citations

Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials

Critical Care2024-11-117 citations

Treatment Outcomes Among Patients With a Positive<i>Candida</i>Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study

Clinical Infectious Diseases2024-07-105 citations

Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults

The Journal of Infectious Diseases2024-03-1915 citations

P29 Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with candidaemia and/or invasive candidiasis: integrated analysis of pooled Phase 2 and Phase 3 data

JAC-Antimicrobial Resistance2024-01-011 citations

Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.

2023-11-2341 citations

Prevention, Diagnosis and Management of Pneumocystis jirovecii Infection in Children With Cancer or Receiving Hematopoietic Cell Therapy

The Pediatric Infectious Disease Journal2023-09-215 citations

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis

JAC-Antimicrobial Resistance2023-06-011 citations

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials

JAC-Antimicrobial Resistance2023-06-011 citations

P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis

JAC-Antimicrobial Resistance2023-06-011 citations

P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis

JAC-Antimicrobial Resistance2023-01-194 citations

231. Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis

Open Forum Infectious Diseases2022-12-012 citations

592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) <i>Candida glabrata</i> Target Attainment (TA)

Open Forum Infectious Diseases2022-12-011 citations

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.

2022-11-25117 citations

Reason and reality—identifying barriers to patient enrolment for clinical trials in invasive candidiasis

Journal of Antimicrobial Chemotherapy2022-10-104 citations

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin

Open Forum Infectious Diseases2021-11-013 citations

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin

Open Forum Infectious Diseases2020-10-012 citations

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial

Clinical Infectious Diseases2020-09-15143 citations

Rezafungin for Injection

Sponsors

Conditions

Phase 3

Related Papers